Latest Shareholder Value News

InFocus Group Holdings has extended its convertible note facility by $1 million, aiming to support growth in Thailand and new ventures in iGaming, pending shareholder approval.

Shriro Holdings reported a 13.6% revenue decline in FY25 amid a strategic shift in its BBQ segment but delivered a 5.5% rise in EBITDA. The company plans a $20 million share buy-back in FY26, signaling confidence in its operational turnaround.

BPH Global Ltd has reported a record-breaking month in its Indonesian seaweed operations, more than doubling previous sales and advancing its export capabilities.

Pengana Capital Group reports a steady increase in Funds Under Management to $3.84 billion as of October 2025, with a significant $69.1 million capital raise set to boost figures in November.

Bryah Resources has secured approvals and land access agreements to begin drilling at its Golden Pike Project in Canada, targeting high-grade gold and antimony deposits with programs set to complete by year-end.

HMC Capital has secured an increased and extended revolving debt facility, enhancing its underwriting capacity and supporting strategic growth initiatives, including its energy transition efforts.

Prominence Energy Ltd has made significant technical progress at its Gawler Hydrogen Project, confirming high-grade natural hydrogen potential and preparing for a major geochemical survey in early 2026. The company also strengthens its global position by joining a prestigious hydrogen delegation to Korea.

Solvar Limited reported solid FY25 results with profit growth, a significant dividend hike, and a positive outlook for FY26 driven by loan originations and commercial lending expansion.

Sarama Resources has raised A$2.7 million to fund exploration at its Australian gold projects while progressing a significant arbitration claim against Burkina Faso for expropriation of its African permit.

Stealth Group Holdings has reported its strongest financial year yet, with record sales and profits, while announcing a major acquisition that promises to reshape its market footprint.

Starpharma’s 2025 AGM highlighted breakthrough partnerships and clinical progress, positioning the biotech for growth. Key deals with Genentech and Radiopharm Theranostics underpin a promising pipeline and expanding revenue streams.

Navigator Global Investments appoints Roger Davis as new Chair and suspends dividends to prioritize capital for growth and new partnerships.